Standard BioTools (NASDAQ:LAB) Releases Earnings Results, Beats Estimates By $0.05 EPS

Standard BioTools (NASDAQ:LAB) posted its earnings results on Tuesday. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.05, FiscalAI reports. Standard BioTools had a net margin of 100.36% and a negative return on equity of 7.57%. The firm had revenue of $19.39 million for the quarter, compared to the consensus estimate of $18.80 million.

Standard BioTools Stock Down 0.8%

NASDAQ:LAB traded down $0.01 during mid-day trading on Thursday, reaching $0.61. 467,524 shares of the stock were exchanged, compared to its average volume of 2,279,531. The stock has a market capitalization of $241.17 million, a P/E ratio of 2.78 and a beta of 1.52. Standard BioTools has a 1 year low of $0.59 and a 1 year high of $1.72. The company has a 50 day simple moving average of $0.68 and a 200-day simple moving average of $0.91.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Standard BioTools from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, August 7th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Reduce”.

About Standard BioTools

Standard BioTools Inc (NASDAQ: LAB) develops and supplies technologies, instruments and consumables used by researchers and biopharmaceutical companies to analyze biological systems. Its portfolio supports applications in proteomics, genomics, single-cell analysis, mass cytometry and spatial biology.

The company’s offerings include the SomaScan protein profiling platform, which measures large numbers of proteins from biological samples, as well as CyTOF mass cytometry systems for high-dimensional single-cell analysis.